Anti-GPR33 monoclonal antibody

Anti-GPR33 antibody for FACS & in-vivo assay

Target products collectionGo to GPR33/GPR33 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0532-Ab-1/ GM-Tg-hg-MP0532-Ab-2Anti-Human GPR33 monoclonal antibodyHuman
GM-Tg-rg-MP0532-Ab-1/ GM-Tg-rg-MP0532-Ab-2Anti-Rat GPR33 monoclonal antibodyRat
GM-Tg-mg-MP0532-Ab-1/ GM-Tg-mg-MP0532-Ab-2Anti-Mouse GPR33 monoclonal antibodyMouse
GM-Tg-cynog-MP0532-Ab-1/ GM-Tg-cynog-MP0532-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR33 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0532-Ab-1/ GM-Tg-felg-MP0532-Ab-2Anti-Feline GPR33 monoclonal antibodyFeline
GM-Tg-cang-MP0532-Ab-1/ GM-Tg-cang-MP0532-Ab-2Anti-Canine GPR33 monoclonal antibodyCanine
GM-Tg-bovg-MP0532-Ab-1/ GM-Tg-bovg-MP0532-Ab-2Anti-Bovine GPR33 monoclonal antibodyBovine
GM-Tg-equg-MP0532-Ab-1/ GM-Tg-equg-MP0532-Ab-2Anti-Equine GPR33 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0532-Ab-1/ GM-Tg-hg-MP0532-Ab-2; GM-Tg-rg-MP0532-Ab-1/ GM-Tg-rg-MP0532-Ab-2;
GM-Tg-mg-MP0532-Ab-1/ GM-Tg-mg-MP0532-Ab-2; GM-Tg-cynog-MP0532-Ab-1/ GM-Tg-cynog-MP0532-Ab-2;
GM-Tg-felg-MP0532-Ab-1/ GM-Tg-felg-MP0532-Ab-2; GM-Tg-cang-MP0532-Ab-1/ GM-Tg-cang-MP0532-Ab-2;
GM-Tg-bovg-MP0532-Ab-1/ GM-Tg-bovg-MP0532-Ab-2; GM-Tg-equg-MP0532-Ab-1/ GM-Tg-equg-MP0532-Ab-2
Products NameAnti-GPR33 monoclonal antibody
Formatmab
Target NameGPR33
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR33 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GPR33 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0532
    Target NameGPR33
    Gene ID2856,14762,299007,106999386,100688257,101087750,788930,100056072
    Gene Symbol and SynonymsGPR33,Gpr33-ps1
    Uniprot AccessionQ49SQ1
    Uniprot Entry NameGPR33_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000214943
    Target ClassificationN/A

    The target: GPR33, gene name: GPR33, also named as . This gene has been identified as an orphan chemoattractant G-protein-coupled receptors (GPCR) pseudogene. Studies have shown that the inactivated gene is present as the predominant allele in the human population. A small fraction of the human population has been found to harbor an intact allele..



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.